Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.73), $0.08 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $71.26 million versus the consensus estimate of $67.53 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.